All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported | 2006-001782-42 | Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin CB-01-05-MMXTM , administered as add-on therapy to oral mesalazine or other 5-ASA derivati... | 2007-12-19 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2006-004776-12 | Efficacy and Safety of Oral Budesonide-MMX (CB 01 02) 6 mg and 9 mg Extended Release Tablets in Patients with Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Doub... | 2010-12-13 | bad-data |
Completed, but no date | 2007-007702-30 | Feasibility and safety of Infliximab enema treatment in patients with active left-sided ulcerative colitis. An open-label, non comparative, pilot study. | bad-data | |
Not reported | 2008-003913-28 | Randomised, double-blind,multicentre,12 months extension study to evaluate the safety and the efficacy of daily Budesonide MMX 6mg vs placebo in the maintenance of remission in subjects with ulcerativ... | 2011-05-16 | due-trials |
Reported results Terminated | 2011-001173-24 | Colon staining efficacy of single oral doses of methylene blue MMX modified release tablets administered to patients undergoing colonoscopy | 2012-01-16 | due-trials |
Reported results | 2011-005693-36 | Intraepithelial neoplasia detection rate after single oral dose of methylene blue MMX modified release tablets administered to patients with long standing ulcerative colitis undergoing colonoscopy ... | 2012-07-04 | due-trials |
Completed, but no date | 2011-005694-23 | Polyp detection rate after single oral dose of methylene blue MMX(R) modified release tablets administered to subjects undergoing outpatients colonoscopy Tasso di rilevamento dei polipi dopo sommin... | bad-data | |
Listed as ongoing, but also has a completion date | 2012-003983-32 | The safety and efficacy of Methylene Blue MMX® modified release tablets administered to subjects undergoing screening or surveillance colonoscopy. | 2016-10-27 | bad-data |
Completed, but no date, and reported results Terminated | 2013-000452-18 | Staining efficacy and safety of Methylene Blue enemas in patients undergoing flexible rectosigmoidoscopy Efficacia della colorazione e sicurezza di clisteri di blu di metilene in pazienti sottopost... | bad-data | |
Completed, but no date, and reported results | 2013-000634-35 | Effect of oral administration of Methylene Blue MMX® tablets on double-stranded DNA damage assessed by γH2AX analysis of colon biopsy samples Effetto della somministrazione orale di Methylene Blu... | bad-data | |
Listed as ongoing, but also has a completion date and reported results | 2016-004977-42 | A Phase II, multicentre, randomised, double-blind, Placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to patien... | 2020-09-10 | bad-data |
Ongoing, reported early | 2017-003505-17 | Colonic lesion staining and flagging efficacy of methylene blue administered as MMX® 25 mg modified release tablets to patients receiving a split dose regimen of bowel cleansing preparation for colono... | not-yet-due |